Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.
2.

Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.

Chung LW, Baseman A, Assikis V, Zhau HE.

J Urol. 2005 Jan;173(1):10-20. Review.

PMID:
15592017
3.

Ecological photodynamic therapy: new trend to disrupt the intricate networks within tumor ecosystem.

Rumie Vittar NB, Lamberti MJ, Pansa MF, Vera RE, Rodriguez ME, Cogno IS, Milla Sanabria LN, Rivarola VA.

Biochim Biophys Acta. 2013 Jan;1835(1):86-99. doi: 10.1016/j.bbcan.2012.10.004. Review.

PMID:
23127970
4.

Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.

Liu W, Vivian CJ, Brinker AE, Hampton KR, Lianidou E, Welch DR.

Cancer Microenviron. 2014 Dec;7(3):117-31. doi: 10.1007/s12307-014-0148-4.

5.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
6.
7.

Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.

Loberg RD, Logothetis CJ, Keller ET, Pienta KJ.

J Clin Oncol. 2005 Nov 10;23(32):8232-41. Review.

PMID:
16278478
8.

The Goal of Cancer Treatment.

Balis FM.

Oncologist. 1998;3(4):V.

PMID:
10388118
9.

Biological stoichiometry in tumor micro-environments.

Kareva I.

PLoS One. 2013;8(1):e51844. doi: 10.1371/journal.pone.0051844.

10.

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Pérez-Herrero E, Fernández-Medarde A.

Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Review.

PMID:
25813885
11.

Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.

Yagata H, Kajiura Y, Yamauchi H.

Breast Cancer. 2011 Jul;18(3):165-73. doi: 10.1007/s12282-011-0254-9. Review. Erratum in: Breast Cancer. 2012 Oct;19(4):369.

PMID:
21290263
12.

Anaplastic thyroid cancer: prevalence, diagnosis and treatment.

Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G.

Minerva Endocrinol. 2008 Dec;33(4):341-57. Review.

PMID:
18923370
13.

A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions.

Loberg RD, Gayed BA, Olson KB, Pienta KJ.

J Cell Biochem. 2005 Oct 15;96(3):439-46. Review.

PMID:
15988761
14.

The analysis of metallothionein immunoreactivity in stromal fibroblasts and macrophages in cases of uterine cervical carcinoma with respect to both the local and distant spread of the disease.

Walentowicz-Sadlecka M, Koper A, Krystyna G, Koper K, Basta P, Mach P, Skret-Magierlo J, Dutsch-Wicherek M, Sikora J, Grabiec M, Kazmierczak W, Wicherek L.

Am J Reprod Immunol. 2013 Sep;70(3):253-61. doi: 10.1111/aji.12120.

PMID:
23590599
15.

Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.

Kim JY, Gatenby RA.

Methods Mol Biol. 2017;1513:61-81.

PMID:
27807831
16.
17.

The biology of hormone refractory prostate cancer. Why does it develop?

Isaacs JT.

Urol Clin North Am. 1999 May;26(2):263-73. Review.

PMID:
10361549
19.

Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles.

Chen KW, Pienta KJ.

Theor Biol Med Model. 2011 Oct 3;8:36. doi: 10.1186/1742-4682-8-36.

20.

Ecological paradigms to understand the dynamics of metastasis.

Amend SR, Roy S, Brown JS, Pienta KJ.

Cancer Lett. 2016 Sep 28;380(1):237-42. doi: 10.1016/j.canlet.2015.10.005.

Items per page

Supplemental Content

Support Center